Drug Information Association to Host Asia Regulatory Conference in Singapore, Spotlighting Regulatory Convergence and Patient Safety Standards
Published: Nov 20, 2012
For three days, health authorities, local and multinational pharmaceutical companies, and clinical research professionals within global regulatory and beyond will attend interactive presentations, exciting sessions, and new opportunities to explore better patient solutions.
Key topics will focus on:
• The future of research and development of safer medicines; • Opening up dialogue with ongoing issues in the regulatory and technical areas in Asia;
• Promote greater unions of regulatory requirements in Asia; and
• Encourage stronger ties between Asian regulatory authorities and pharmaceutical industry.
The Opening Ceremony will begin with Welcome Remarks from Dr. Ling Su, President, DIA Board of Directors and Life Sciences Consultant, Sidley Austin LLP, China. Additionally a welcome from Mr. Toshiaki Miyoshi, Managing Director, JPMA, Japan, on behalf of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Japan Pharmaceutical Manufacturers Association (JPMA) and Dr. John C. W. Lim Chief Executive Officer, Health Sciences Authority (HSA), Singapore will open the sessions.
“This meeting marks a turning point for DIA and its regions, especially in the Asian sector. We are striving to provide the best information globally to better serve our entire client base and all pharmaceutical, medical product, and regulatory professionals. This conference will specialize in corralling ongoing efforts to increase patient access to new and improved medicines,” maintains DIA Worldwide Director Paul Pomerantz.
Register for the Asia Regulatory Conference 2013 in Singapore here. Follow the hashtag #AsiaRegConfDIA2013 on Twitter for meeting updates and conference information.
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related medical products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; and Beijing, China. www.diahome.org. Follow DIA on Facebook, Twitter, LinkedIn, and YouTube. Stay updated on hot topic news at #druginfoassn on Twitter.
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 1.3 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Health Sciences Authority (HSA) is a statutory board of the Singapore Ministry of Health consisting of three Professional Groups: the Applied Sciences Group, the Blood Services Group and the Health Products Regulation Group. Its vision is to be the leading innovative authority protecting and advancing national health and safety.